SFN抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02230(SFN Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P02230(SFN Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Stratifin (SFN), also known as 14-3-3 sigma, is a member of the 14-3-3 protein family, which comprises conserved regulatory molecules involved in diverse cellular processes, including cell cycle control, apoptosis, and signal transduction. SFN specifically regulates G2/M cell cycle checkpoints by binding to phosphorylated client proteins, such as CDK1 and p53. to coordinate DNA damage responses. Its expression is often dysregulated in cancers, functioning as a tumor suppressor in epithelial tissues. Loss of SFN is associated with poor prognosis in breast, lung, and gastric cancers, while its overexpression may correlate with chemoresistance.

SFN antibodies are essential tools for detecting and quantifying SFN protein levels in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study SFN's role in cancer biology, DNA repair mechanisms, and cellular stress responses. Commercially available SFN antibodies are typically raised against specific epitopes, such as the C-terminal region, and validated for specificity across human and model organisms. Recent studies also explore SFN's potential as a biomarker for personalized oncology, driving demand for reliable antibodies in translational research. Understanding SFN's interaction networks through antibody-based assays continues to reveal its dual roles in tumor suppression and therapy resistance.